Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.

Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, Grove B, Dye A, Bridger G.

Bone Marrow Transplant. 2008 Feb;41(4):331-8. Epub 2007 Nov 12.

PMID:
17994119
2.

Plerixafor: a peripheral blood stem cell mobilizer.

Kessans MR, Gatesman ML, Kockler DR.

Pharmacotherapy. 2010 May;30(5):485-92. doi: 10.1592/phco.30.5.485. Review.

PMID:
20411999
3.

Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.

Choi HY, Yong CS, Yoo BK.

Ann Pharmacother. 2010 Jan;44(1):117-26. doi: 10.1345/aph.1M380. Epub 2009 Dec 15. Review.

PMID:
20009003
4.

The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).

De Clercq E.

Biochem Pharmacol. 2009 Jun 1;77(11):1655-64. doi: 10.1016/j.bcp.2008.12.014. Epub 2008 Dec 31. Review.

PMID:
19161986
5.

Management strategies for the hard-to-mobilize patient.

Stiff PJ.

Bone Marrow Transplant. 1999 May;23 Suppl 2:S29-33. Review.

6.

[Collection of hematopoietic progenitor cells from healthy donors].

Bojanić I, Cepulić BG, Mazić S.

Acta Med Croatica. 2009 Jun;63(3):237-44. Review. Croatian.

PMID:
19827352
7.

Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.

Keating GM.

Drugs. 2011 Aug 20;71(12):1623-47. doi: 10.2165/11206040-000000000-00000. Review.

PMID:
21861545
8.

Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.

Jantunen E, Fruehauf S.

Bone Marrow Transplant. 2011 May;46(5):627-35. doi: 10.1038/bmt.2010.320. Epub 2011 Jan 10. Review.

PMID:
21217789
9.

Peripheral blood stem cell mobilization tactics.

Rosenbeck LL, Srivastava S, Kiel PJ.

Ann Pharmacother. 2010 Jan;44(1):107-16. doi: 10.1345/aph.1M289. Epub 2009 Dec 8. Review.

PMID:
19996324
10.

The use of growth factors in hematopoietic stem cell transplantation.

Pusic I, DiPersio JF.

Curr Pharm Des. 2008;14(20):1950-61. Review.

PMID:
18691106
11.

Management strategies for poor peripheral blood stem cell mobilization.

Moog R.

Transfus Apher Sci. 2008 Jun;38(3):229-36. doi: 10.1016/j.transci.2008.04.002. Epub 2008 May 15. Review.

PMID:
18485822
12.

Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.

Uy GL, Rettig MP, Cashen AF.

Expert Opin Biol Ther. 2008 Nov;8(11):1797-804. doi: 10.1517/14712598.8.11.1797 . Review.

PMID:
18847313
13.
14.

Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.

Pusic I, DiPersio JF.

Curr Opin Hematol. 2010 Jul;17(4):319-26. doi: 10.1097/MOH.0b013e328338b7d5. Review.

PMID:
20473162
15.

Can every patient be mobilized?

DiPersio JF.

Best Pract Res Clin Haematol. 2010 Dec;23(4):519-23. doi: 10.1016/j.beha.2010.09.011. Epub 2010 Nov 18. Review.

PMID:
21130416
16.

Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.

Jantunen E, Lemoli RM.

Transfusion. 2012 Apr;52(4):906-14. doi: 10.1111/j.1537-2995.2011.03349.x. Epub 2011 Oct 7. Review.

PMID:
21981351
17.

Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells.

Flomenberg N, DiPersio J, Calandra G.

Acta Haematol. 2005;114(4):198-205. Review.

PMID:
16269859
18.

Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?

Cashen AF, Lazarus HM, Devine SM.

Bone Marrow Transplant. 2007 May;39(10):577-88. Epub 2007 Mar 19. Review.

PMID:
17369869
19.

Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation.

Schmitt M, Publicover A, Orchard KH, Görlach M, Wang L, Schmitt A, Mani J, Tsirigotis P, Kuriakose R, Nagler A.

Theranostics. 2014 Jan 23;4(3):280-9. doi: 10.7150/thno.7752. eCollection 2014. Review.

20.

Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.

De Clercq E.

Pharmacol Ther. 2010 Dec;128(3):509-18. doi: 10.1016/j.pharmthera.2010.08.009. Epub 2010 Sep 15. Review.

PMID:
20826182

Supplemental Content

Support Center